Bayer to present cardiac amyloidosis, heart failure data at HFSA

Bayer said it will present late-breaking and poster data from its cardiovascular portfolio at the Heart Failure Society of America annual meeting. The materials include a Phase III post-hoc analysis of investigational iodine 124 evuzamitide and study designs for ongoing finerenone trials.